Correlation of early metastatic response by 123I-metaiodobenzylguanidine scintigraphy with overall response and event-free survival in stage IV neuroblastoma - PubMed (original) (raw)
. 2003 Jul 1;21(13):2486-91.
doi: 10.1200/JCO.2003.09.122.
Affiliations
- PMID: 12829667
- DOI: 10.1200/JCO.2003.09.122
Correlation of early metastatic response by 123I-metaiodobenzylguanidine scintigraphy with overall response and event-free survival in stage IV neuroblastoma
Katherine K Matthay et al. J Clin Oncol. 2003.
Abstract
Purpose: Metaiodobenzylguanidine (MIBG), specifically taken up in cells of sympathetic origin, provides a highly sensitive and specific indicator for the detection of metastases in neuroblastoma. The aim of this study was to correlate early response to therapy by MIBG scan, using a semiquantitative scoring method, with the end induction response and event-free survival (EFS) rate in stage IV neuroblastoma.
Patients and methods: Seventy-five children older than 1 year and with stage IV neuroblastoma had 123I-MIBG scans at diagnosis, after two and four cycles of induction therapy, and before autologous stem-cell transplantation. The scans were read by two independent observers (concordance > 95%) using a semiquantitative method. Absolute and relative (score divided by initial score) MIBG scores were then correlated with overall pretransplantation response, bone marrow response, and EFS.
Results: The pretransplantation response rate was 81%, and the 3-year EFS rate was 32%, similar to a concomitant group of 375 stage IV patients. The median relative MIBG scores after two, four, and six cycles were 0.5, 0.24, and 0.12, respectively. The probability of having a complete response or very good partial response before transplantation was significantly higher if the relative score after two cycles was < or = 0.5, or, if after four cycles, the relative score was < or = 0.24. Patients with a relative score of < or = 0.5 after two cycles or a score of < or = 0.24 after four cycles had an improved EFS rate (P =.053 and.045, respectively).
Conclusion: Semiquantitative MIBG score early in therapy provides valuable prognostic information for overall response and EFS, which may be useful in tailoring treatment.
Similar articles
- Iodine-123 metaiodobenzylguanidine scintigraphy scoring allows prediction of outcome in patients with stage 4 neuroblastoma: results of the Cologne interscore comparison study.
Decarolis B, Schneider C, Hero B, Simon T, Volland R, Roels F, Dietlein M, Berthold F, Schmidt M. Decarolis B, et al. J Clin Oncol. 2013 Mar 1;31(7):944-51. doi: 10.1200/JCO.2012.45.8794. Epub 2013 Jan 22. J Clin Oncol. 2013. PMID: 23341514 - Scintigraphic response by 123I-metaiodobenzylguanidine scan correlates with event-free survival in high-risk neuroblastoma.
Katzenstein HM, Cohn SL, Shore RM, Bardo DM, Haut PR, Olszewski M, Schmoldt J, Liu D, Rademaker AW, Kletzel M. Katzenstein HM, et al. J Clin Oncol. 2004 Oct 1;22(19):3909-15. doi: 10.1200/JCO.2004.07.144. J Clin Oncol. 2004. PMID: 15459212 Clinical Trial. - The prognostic impact of functional imaging with (123)I-mIBG in patients with stage 4 neuroblastoma >1 year of age on a high-risk treatment protocol: results of the German Neuroblastoma Trial NB97.
Schmidt M, Simon T, Hero B, Schicha H, Berthold F. Schmidt M, et al. Eur J Cancer. 2008 Jul;44(11):1552-8. doi: 10.1016/j.ejca.2008.03.013. Epub 2008 Apr 16. Eur J Cancer. 2008. PMID: 18424129 Clinical Trial. - MIBG scintigraphy for the diagnosis and follow-up of children with neuroblastoma.
Boubaker A, Bischof Delaloye A. Boubaker A, et al. Q J Nucl Med Mol Imaging. 2008 Dec;52(4):388-402. Q J Nucl Med Mol Imaging. 2008. PMID: 19088693 Review.
Cited by
- The prognostic role of 18F-FDG PET/CT-based response evaluation in children with stage 4 neuroblastoma.
Lu X, Li C, Wang S, Yin Y, Fu H, Wang H, Cheng W, Chen S. Lu X, et al. Eur Radiol. 2024 Nov;34(11):7125-7135. doi: 10.1007/s00330-024-10781-w. Epub 2024 May 17. Eur Radiol. 2024. PMID: 38758254 - Naxitamab Combined with Granulocyte-Macrophage Colony-Stimulating Factor as Consolidation for High-Risk Neuroblastoma Patients in First Complete Remission under Compassionate Use-Updated Outcome Report.
Mora J, Castañeda A, Gorostegui M, Varo A, Perez-Jaume S, Simao M, Muñoz JP, Garraus M, Larrosa C, Salvador N, Lavarino C, Krauel L, Mañe S. Mora J, et al. Cancers (Basel). 2023 Apr 28;15(9):2535. doi: 10.3390/cancers15092535. Cancers (Basel). 2023. PMID: 37174002 Free PMC article. - Individualized risk assessment in neuroblastoma: does the tumoral metabolic activity on 123I-MIBG SPECT predict the outcome?
Rogasch JMM, Hundsdoerfer P, Furth C, Wedel F, Hofheinz F, Krüger PC, Lode H, Brenner W, Eggert A, Amthauer H, Schatka I. Rogasch JMM, et al. Eur J Nucl Med Mol Imaging. 2017 Dec;44(13):2203-2212. doi: 10.1007/s00259-017-3786-1. Epub 2017 Aug 14. Eur J Nucl Med Mol Imaging. 2017. PMID: 28808732 - Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting.
Park JR, Bagatell R, Cohn SL, Pearson AD, Villablanca JG, Berthold F, Burchill S, Boubaker A, McHugh K, Nuchtern JG, London WB, Seibel NL, Lindwasser OW, Maris JM, Brock P, Schleiermacher G, Ladenstein R, Matthay KK, Valteau-Couanet D. Park JR, et al. J Clin Oncol. 2017 Aug 1;35(22):2580-2587. doi: 10.1200/JCO.2016.72.0177. Epub 2017 May 4. J Clin Oncol. 2017. PMID: 28471719 Free PMC article. Review. - Comparative genetic study of intratumoral heterogenous MYCN amplified neuroblastoma versus aggressive genetic profile neuroblastic tumors.
Berbegall AP, Villamón E, Piqueras M, Tadeo I, Djos A, Ambros PF, Martinsson T, Ambros IM, Cañete A, Castel V, Navarro S, Noguera R. Berbegall AP, et al. Oncogene. 2016 Mar 17;35(11):1423-32. doi: 10.1038/onc.2015.200. Epub 2015 Jun 29. Oncogene. 2016. PMID: 26119945
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical